# Efficacy of Nerve Blocks for Episodic Migraine

> **NCT05734625** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 60 (estimated)

## Conditions studied

- Episodic Migraine

## Interventions

- **DRUG:** Bupivacaine HCl 0.5% Injectable Solution
- **DRUG:** Methylprednisolone 40 MG Injection

## Key facts

- **NCT ID:** NCT05734625
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-10
- **Primary completion:** 2027-02
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05734625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05734625, "Efficacy of Nerve Blocks for Episodic Migraine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05734625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*